Evidence map›Paper›PMID 40877142›Full record

ReviewIn vivo (Athens, Greece)

Lipofibromatosis Revisited.

Yuki Shinohara, Jun Nishio, Shizuhide Nakayama, Mikiko Aoki

Abstract readReview
In one paragraph

Review in In vivo (Athens, Greece). The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Review
  2. Fibronectin 1 (Cancer genomics & proteomics
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors.

Yuki Shinohara *Section of Orthopaedic Surgery, Department of Medicine, Fukuoka Dental College, Fukuoka, Japan.
Jun Nishio *Section of Orthopaedic Surgery, Department of Medicine, Fukuoka Dental College, Fukuoka, Japan; nishio@fdcnet.ac.jp.
Shizuhide NakayamaNakayama Orthopaedic Clinic, Fukuoka, Japan.
Mikiko AokiDepartment of Pathology, Faculty of Medicine, Fukuoka University, Fukuoka, Japan.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Lipofibromatosis (LPF) is a locally aggressive but non-metastasizing mesenchymal tumor that primarily occurs in the hands and feet of infants and young children. It typically presents as a slow-growing, painless, poorly demarcated subcutaneous mass. Magnetic resonance imaging reveals the lesion to be a poorly defined mass with a mixture of adipose and fibrous components. Variable enhancement is seen after intravenous contrast administration. Histologically, LPF displays a distinctive admixture of mature adipose tissue and short fascicles of bland spindle cells. By immunohistochemistry, the spindle cells are moderately or diffusely positive for CD34 and CD99, focally positive for smooth muscle actin but typically negative for S-100 protein, desmin, β-catenin and pan-tropomyosin receptor kinase (TRK). Recent molecular studies have shown a variety of fusions involving epidermal growth factor receptor (EGFR) ligands or EGFR itself or other receptor tyrosine kinases, suggesting a shared deregulation of the phosphatidylinositol 3-kinase (PI3K)/AKT/mammalian target of the rapamycin (mTOR) pathway. Complete surgical excision with preservation of adjacent neurovascular structures is the treatment of choice for LPF. This review provides an updated overview of the clinical, radiological, histological, immunohistochemical, cytogenetic and molecular genetic features of LPF and discusses the relationship to LPF-like neural tumor.

Indexed as

FibromaLipomaSoft Tissue NeoplasmsBiomarkers, TumorHumansImmunohistochemistryMagnetic Resonance ImagingBiomarkers, TumorCD34Lipofibromatosislipofibromatosis-like neural tumorNTRKreviewS-100 protein

Identifiers

PMID40877142
PMCPMC12396084

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.